Results 81 to 90 of about 41,281 (176)

Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates

Chemical Biology &Drug Design, Volume 107, Issue 6, June 2026.
Three decades of cruzain‐targeted drug discovery have yielded 215 sub‐micromolar inhibitors but no clinical candidates. This review diagnoses a systemic translational failure driven by single‐parameter optimisation and proposes a multiparametric framework integrating enzymatic potency, cathepsin selectivity, intracellular exposure, and metabolic ...
Caroline Rodrigues Chaves dos Reis, Hellen Valério Chaves Moura de Souza, Lidia Corrêa Parra, Guilber Valério Chaves Moura de Souza, Bruna Costa Zorzanelli, Nubia Boechat, Lucas Villas Bôas Hoelz, Tácio Vinício Amorim Fernandes   +7 more
wiley   +1 more source

Effect of quercetin on the transport of ritonavir to the central nervous system in vitro and in vivo

Acta Pharmaceutica, 2016
The aim of this study was to identify an effective flavonoid that could improve the intracellular accumulation of ritonavir in human brain-microvascular endothelial cells (HBMECs). An in vivo experiment on Sprague-Dawley rats was then designed to further
Liang Gongwen, Li Na, Ma Liping, Qian Zhonglian, Sun Yuwen, Shi Luwen, Zhao Libo   +6 more
doaj   +1 more source

Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT QT interval prolongation associated with drug administration is an important consideration in drug development. Patients with COVID‐19 are at increased risk for cardiac complications, and QT interval prolongation correlates with higher mortality.
Chi‐Chi Peng, Ran Duan, Mazin Abdelghany, Santosh Davies, Deqing Xiao, Anna Kwan, Ana Ruiz‐Garcia   +6 more
wiley   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, Volume 27, Issue 6, Page 918-934, June 2026.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, Volume 27, Issue 6, Page 965-978, June 2026.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

Infection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N, Yu X, Li L, Yang P, Dong R, Huang Y, Ling X, Shentu Q, Yu W, Jiang S   +9 more
doaj  

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease
Background and Aim Simnotrelvir/ritonavir and nirmatrelvir/ritonavir are major treatments for COVID‐19, but their comparative efficacy and safety, especially in patients with moderate to severe COVID‐19, remain unclear.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
doaj   +1 more source

Physiologically‐based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co‐administered with ritonavir

CPT: Pharmacometrics & Systems Pharmacology
GLS4 is a first‐in‐class hepatitis B virus (HBV) capsid assembly modulator (class I) that is co‐administered with ritonavir to maintain the anticipated concentration required for the effective antiviral activity of GLS4.
Zexu Sun, Nan Zhao, Ran Xie, Bo Jia, Junyu Xu, Lin Luo, Yulei Zhuang, Yuyu Peng, Xinchang Liu, Yingjun Zhang, Xia Zhao, Zhaoqian Liu, Yimin Cui   +12 more
doaj   +1 more source

Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era. [PDF]

ACG Case Rep J
DeBroff J, Abraham J, Yoon BH, Cohen I.
europepmc   +1 more source